|
Elena's Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
Robotics are reshaping biologics manufacturing, Novo submitted a sickle cell drug, and immunology biotech Windward Bio debuted on Nasdaq after a $17 IPO.
The top 10 stories from Fri Nov 13, 2026 06:49 AM to Mon Nov 16, 2026 06:45 AM
Generated November 16, 2026 at 6:45 AM
|
|
|
#1 Innovative Immunology Biotech Windward Bio Lists on Nasdaq Published 2026-11-14 Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, listed on Nasdaq on November 13, 2026, after pricing its IPO at $17 per share. Covered by: prnewswire.com, insights.citeline.com, biospace.com |
#2 Sino Biological Launches 4RISE™ High-Throughput Wet-Lab Services to Accelerate AI-Driven Drug Discovery Published 2026-11-13 Sino Biological announced 4RISE, a high-throughput wet-lab service designed to validate whether AI-designed protein binders bind their intended targets. Covered by: prnewswire.com, prnewswire.com |
#3 Ambrosia Biosciences Announces the Nonclinical Data Profiles of Two Oral Small Molecule Programs: A GLP-1 Receptor Agonist Intended for Once-Weekly Dosing and a GIP Receptor Antagonist Published 2026-11-15 Ambrosia Biosciences presented preclinical data on two oral drug candidates: a GLP-1 receptor agonist designed for weekly dosing and a GIP receptor antagonist. Covered by: prnewswire.com |
#4 George Church quits AI startup; Ira Mellman’s immunotherapy fight; and more Published 2026-11-14 The newsletter previews George Church’s departure from an AI startup and Ira Mellman’s immunotherapy dispute, alongside other biotech news. Covered by: endpoints.news |
#5 Bay Area based Multiply Labs gave BiotechTV a behind the scenes look at the state of the art robotics that are being used today to manufacture advanced biologics and other modalities Published 2026-11-13 Multiply Labs showed BiotechTV how robotics are being used to manufacture advanced biologics, with CEO Fred Parietti describing a shift from processes partly done by hand. Covered by: biotechtv.com |
#6 China’s innovation moment sees a rise in first in class Published 2026-11-14 BioCentury’s analysis for the 2026 China Healthcare Summit examines the rise of first-in-class innovation in China. Covered by: biocentury.com |
#7 StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations? Published 2026-11-15 Nvidia’s board named CFO Colette Kress interim CEO after Jensen Huang resigned amid reported affairs and an investigation, raising questions about the company’s life sciences collaborations. Covered by: genengnews.com |
#8 Sofinnova books biggest-ever $815M fund with an eye toward up-and-coming ‘global leaders’ Published 2026-11-16 Sofinnova Partners closed an $815 million fund, its largest to date, to back about 15 clinical-stage companies, mostly in Europe. Covered by: fiercebiotech.com |
#9 This week in charts: Brain drugs are back on venture capitalists’ minds Published 2026-11-13 Five neurology-focused startups raised about $450 million in recent weeks, while investors responded cautiously to new cell therapy research. Covered by: biopharmadive.com |
#10 Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties Published 2026-11-13 Novo submitted a sickle cell drug, while Flagship and the Gates Foundation deepened their partnership. Covered by: biopharmadive.com |